A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
NCT06419205
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- IgA Nephropathy
- Lupus Nephritis (LN)
- C3 (Complement Component 3) Glomerulopathy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Akebia Therapeutics
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Investigator Site #3 · Hollywood, FL
Georgia · 1
- Investigator Site #1 · Lawrenceville, GA
South Carolina · 1
- Investigator Site #4 · Orangeburg, SC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.